Mantle cell lymphoma is a rare kind of blood cancer caused by excessive lymphocyte proliferation. Mantle cell lymphoma is a type of B-cell non-Hodgkin lymphoma that develops from tumors in the lymph nodes, enters the bloodstream, and spreads to the bone marrow, digestive system, spleen, and liver. Loss of appetite, weight loss, fever, nausea, and vomiting are all common symptoms of the condition. The type of treatment for a patient with Mantle Cell Lymphoma Treatment Market is determined by several criteria, including the patient's age and overall condition. The Food and Drug Administration (FDA) of the United States accepted a supplemental new drug application for bortezomib (Velcade) in 2012, which upgrades the existing label to include.
Over the projected period, the rising prevalence of mantle cell lymphoma is expected to accelerate growth in the mantle cell lymphoma therapy market.
The rising prevalence of mantle cell lymphoma, as well as increased research and development activities in the healthcare industry, are major factors driving growth in the Mantle Cell Lymphoma Treatment Market. This has resulted in a potential product pipeline. According to a 2017 Drug Development Technology study, an estimated 3,300 new cases of mantle cell lymphoma are detected in the United States each year. With federal agency approval, the mantle cell lymphoma treatment market is projected to acquire significant traction. For example, AstraZeneca got FDA approval for Calquence in October 2017 through the FDA's fast approval pathway for the treatment of adults with mantle cell lymphoma.
F.Hoffman La Roche Ltd., Abbvie, Inc., Kite Pharma, Inc., Bayer AG, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, GlaxoSmithKline Plc, Amgen, Inc., Gilead Sciences, Inc., and Johnson & Johnson are key participants in the global mantle cell lymphoma therapy market.
Comments
Post a Comment